Nirmatrelvir/Ritonavir May Not Benefit Patients With Post-Acute Sequelae Of SARS-CoV-2 Infection, Research Finds

Healio (7/9, Cooper) reports, “A 15-day course of Paxlovid [nirmatrelvir/ritonavir] demonstrated no significant benefit for patients with post-acute sequelae of SARS-CoV-2 infection, according to data.” But, “the researchers noted that Paxlovid...was ‘generally safe’ in the cohort of mostly vaccinated patients.” The findings were published in JAMA Internal Medicine.